Skip to content
Triangle logo TriangleGet started
← Full study record

NCT03762018 · OUTCOME

Adverse Events

BEAT-meso: Bevacizumab and Atezolizumab in Malignant Pleural Mesothelioma · Source last updated 2026-07-22

Results reported by the registry submitting party. Population, time horizon, units and missing values must be read together.

Measure
COUNT_OF_PARTICIPANTS
Unit
Participants
Interval / dispersion
Not reported
Time frame
From randomization to 90 days after the last dose of protocol treatment, up to 52 months.

What was measured

Adverse events, according to CTCAE v5.0.

Analysis population: Safety population, patients who received at least 1 dose of treatment: 198 in ABC/200 in BC. But, one patient assigned in the BC arm received ABC. For the safety analysis, the patient is evaluated according to the treatment received irrespective of the allocated treatment at randomization (safety population: 199 in each arm). Of note, in the next section, all-cause mortality was assessed for all randomized, while serious adverse events/adverse events were assessed for the safety population.

Groups in this outcome

Atezolizumab Plus Bevacizumab Plus Chemotherapy

Atezolizumab 1200mg intravenously on day 1 every 3 weeks plus bevacizumab 15mg/kg intravenously on day 1 every 3 weeks plus 4-6 cycles of carboplatin AUC 5 plus pemetrexed 500mg/m\^2 intravenously on day 1 every 3 weeks

Bevacizumab Plus Chemotherapy

Bevacizumab 15mg/kg intravenously on day 1 every 3 weeks plus 4-6 cycles of carboplatin AUC 5 plus pemetrexed 500mg/m\^2 intravenously on day 1 every 3 weeks

Group identifiers and denominators belong to this outcome only. They may differ in another outcome or in safety reporting.

Analysis denominator · Participants

GroupSource count
Atezolizumab Plus Bevacizumab Plus Chemotherapy199
Bevacizumab Plus Chemotherapy199

Reported measurements

Experienced AE/SAE

Experienced AE/SAE

Values in Participants · Interval/dispersion: Not reported
GroupValueSpreadLowerUpperComment
Atezolizumab Plus Bevacizumab Plus Chemotherapy197Not reportedNot reportedNot reportedNot reported
Bevacizumab Plus Chemotherapy197Not reportedNot reportedNot reportedNot reported
Experienced SAE

Experienced AE/SAE

Values in Participants · Interval/dispersion: Not reported
GroupValueSpreadLowerUpperComment
Atezolizumab Plus Bevacizumab Plus Chemotherapy92Not reportedNot reportedNot reportedNot reported
Bevacizumab Plus Chemotherapy67Not reportedNot reportedNot reportedNot reported
Complete source fields
classes
  1. categories
    1. measurements
      1. group Id
        OG000
        value
        197
      2. group Id
        OG001
        value
        197
      title
      Experienced AE/SAE
    title
    Experienced AE/SAE
  2. categories
    1. measurements
      1. group Id
        OG000
        value
        92
      2. group Id
        OG001
        value
        67
      title
      Experienced AE/SAE
    title
    Experienced SAE
denoms
  1. counts
    1. group Id
      OG000
      value
      199
    2. group Id
      OG001
      value
      199
    units
    Participants
description
Adverse events, according to CTCAE v5.0.
groups
  1. description
    Atezolizumab 1200mg intravenously on day 1 every 3 weeks plus bevacizumab 15mg/kg intravenously on day 1 every 3 weeks plus 4-6 cycles of carboplatin AUC 5 plus pemetrexed 500mg/m\^2 intravenously on day 1 every 3 weeks
    id
    OG000
    title
    Atezolizumab Plus Bevacizumab Plus Chemotherapy
  2. description
    Bevacizumab 15mg/kg intravenously on day 1 every 3 weeks plus 4-6 cycles of carboplatin AUC 5 plus pemetrexed 500mg/m\^2 intravenously on day 1 every 3 weeks
    id
    OG001
    title
    Bevacizumab Plus Chemotherapy
param Type
COUNT_OF_PARTICIPANTS
population Description
Safety population, patients who received at least 1 dose of treatment: 198 in ABC/200 in BC. But, one patient assigned in the BC arm received ABC. For the safety analysis, the patient is evaluated according to the treatment received irrespective of the allocated treatment at randomization (safety population: 199 in each arm). Of note, in the next section, all-cause mortality was assessed for all randomized, while serious adverse events/adverse events were assessed for the safety population.
reporting Status
POSTED
time Frame
From randomization to 90 days after the last dose of protocol treatment, up to 52 months.
title
Adverse Events
type
SECONDARY
unit Of Measure
Participants

Download exact source JSON → · Snapshot ctgov-results-25a395029948b04d52b1253f

Preserved source evidence · Not medical advice